ACE-031 and BPC-157 Interaction

Avoid
Mechanism-based 49% confidence

ACE-031 and BPC-157 have a potentially harmful interaction with 49% confidence. Both ACE-031 and BPC-157 have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. These compounds primarily affect different organ systems.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Half-life: 12-15 days Typical dose: 0.5-3 mg/kg IV every 2 weeks (clinical research doses only) growth hormone, anabolic
actriibmyostatintgf beta androgenicanticoagulantblood pressure raisinghpta suppressive
View full profile

BPC-157

Body Protection Compound-157 | Pentadecapeptide

Promotes blood vessel formation (angiogenesis), enhances collagen synthesis, modulates growth factor expression including VEGF, and protects against tissue damage through localized or systemic delivery pathways..

Half-life: <30 minutes Typical dose: 250-500mcg healing, longevity
vegf anticoagulantcarcinogenic riskpro angiogenicteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
low
Liver
low
Pituitary
low
Blood Vessels
low

Shared Safety Flags

2x 2 compounds share the anticoagulant safety flag (ACE-031, BPC-157). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (ACE-031, BPC-157). Monitor accordingly.

Frequently Asked Questions

Can I take ACE-031 with BPC-157?

Combining ACE-031 with BPC-157 is not recommended. Both ACE-031 and BPC-157 have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision.

Is ACE-031 and BPC-157 safe together?

This combination carries significant risk. Both ACE-031 and BPC-157 have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. Consult a healthcare professional before combining.

What are the interactions between ACE-031 and BPC-157?

Both ACE-031 and BPC-157 have anticoagulant or blood-thinning effects. Combined use significantly increases bleeding risk. Avoid unless under direct medical supervision. This assessment has 49% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and BPC-157?

ACE-031 has a half-life of 12-15 days and BPC-157 has a half-life of <30 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: ACE-031 vs BPC-157

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.